Box News

Ashwagandha (Withania somnifera) influences the immune system through several complementary actions that researchers have documented mainly in cells and animals, with growing but still limited clinical data in humans. At a molecular level, bioactive compounds in the plant — especially a group called withanolides (for example withaferin A) and related steroidal lactones — interfere with inflammatory signalling pathways such as NF-κB and MAPK. By damping those pathways, ashwagandha reduces production of pro-inflammatory cytokines (for example TNF-α, IL-6 and IL-1β) and reactive oxygen species, which helps limit excessive inflammation in injured or stressed tissues. (PMC)

At the level of innate immunity, multiple preclinical studies report that extracts of ashwagandha can increase the activity of natural killer (NK) cells, enhance macrophage phagocytosis, and support chemotaxis — all actions that improve the body’s first-line defenses against infected or abnormal cells. These effects appear to be dose- and extract-dependent and are attributed to both direct effects of withanolides on immune cells and indirect effects via reduced oxidative stress. (PMC)

For adaptive immunity, the herb has been shown to modulate T-cell responses: several studies report a tendency to shift immune balance toward a Th1-type response (with higher interferon-γ and IL-2) and to normalize overactive Th2 responses (which drive allergy and some chronic inflammations). This “rebalancing” can also include altered B-cell activity and antibody production in experimental models, which is why researchers have tested ashwagandha as a potential vaccine adjuvant. However, human clinical evidence for improved vaccine responses or broad adaptive-immune enhancement is still preliminary. (ScienceDirect)

Putting those findings together, the practical picture is that ashwagandha acts both to restrain harmful, excessive inflammation and to support cellular immune functions that clear pathogens or abnormal cells. This combined profile — anti-inflammatory plus immune-supportive — is why the herb is described as “immunomodulatory” rather than simply an immune stimulant. That distinction matters clinically: a true immunomodulator can reduce damaging inflammation in some contexts while preserving or even enhancing protective immune responses in others. (MDPI)

Finally, it’s important to be cautious about translating laboratory findings directly into clinical recommendations. Most mechanistic and efficacy data come from in vitro or animal studies and from small human trials with variable extracts and doses; high-quality, large randomized controlled trials are still needed to establish effective regimens, clear indications, and safety in people with immune disorders or those taking immunomodulatory drugs. If you’re considering ashwagandha for immune-related reasons, discuss it with a clinician, especially when you have a chronic illness or take prescription medicines. (PMC)

(Source : ChatGPT)

Laboratory and animal studies show neuroprotective actions for ashwagandha (Withania somnifera), and a handful of small human trials report modest cognitive benefits, but the clinical evidence is still preliminary and larger, longer studies are needed.

Researchers have studied ashwagandha for brain protection in two broad ways: first, by testing purified compounds from the plant (notably the withanolides such as withaferin A and related molecules) and second, by testing whole-root extracts in cells, animals and small human trials. In cell and animal experiments these compounds reduce oxidative stress and inflammation in brain tissue, help neurons resist toxic insults, and encourage processes that support neuron health such as neurite outgrowth and synaptic function. For example, several laboratory studies show that ashwagandha extracts can blunt the damage caused by beta-amyloid (a protein linked to Alzheimer’s disease), reduce markers of inflammation and cell death, and improve memory-related behavior in rodent models. These mechanistic and animal findings are summarized in recent reviews of the literature. (American Chemical Society)

How does it do that? The proposed mechanisms are familiar ones for a botanical with neuroprotective activity: antioxidant effects that lower harmful free radicals; anti-inflammatory actions that reduce damaging immune signaling in the brain; modulation of stress pathways (for example reducing excessive glucocorticoid/HPA-axis activation) that otherwise hurt neurons over time; and direct effects on protein handling and neuronal structure that can reduce toxic protein aggregation and support synapse formation. Specific chemicals from the plant — withanolides and sitoindosides — have been shown in lab work to engage these pathways, although which compound (or combination) matters for which effect is still being mapped out. (American Chemical Society)

What about human evidence? A handful of randomized, placebo-controlled trials have tested standardized root extracts in people. Some studies in stressed adults and in people with mild cognitive impairment report improved memory, attention and processing speed after several weeks to a few months of supplementation, and these trials generally reported good tolerability. However, the trials are small, used different extract preparations and doses, and often measured subjective or short-term endpoints — so while the results are encouraging, they do not yet prove that ashwagandha prevents or reverses major neurodegenerative diseases in people. Larger, longer and better-standardized clinical trials are underway or have been registered. (PubMed)

In plain terms: think of ashwagandha as a botanical that contains molecules able to protect nerve cells in laboratory settings and to nudge human cognition modestly in some small trials. That biological plausibility (antioxidant, anti-inflammatory, anti-amyloid and neurotrophic effects) makes it a promising candidate for further study, but the current human evidence is not yet strong enough to treat it as a proven therapy for Alzheimer’s, Parkinson’s or other major brain diseases. If you’re considering it for memory or brain health, it’s sensible to discuss it with a clinician — especially because product quality, dose and interactions vary. (PMC)

(Source : ChatGPT) (Image : Grok)

Prompt :  Here (x) you said that Ashwagandha had anticancer properties, but in this article it says it doesn't (x) according to Memorial Sloan Kettering Cancer Center Integrative Medicine Service Pharmacist Jason Hou. If it have anticancer properties please write a plain language text (not a bullet point list) explaining the science behind it.

A :  Short answer first: Memorial Sloan Kettering is correct that there’s no strong clinical evidence yet that ashwagandha cures or prevents cancer in people — most of the anti-cancer data come from cells and animals. That said, scientists have identified multiple plausible biochemical ways that ashwagandha’s chemicals (especially a molecule called withaferin A) can damage cancer cells or make tumors more vulnerable to treatment in laboratory models. (Memorial Sloan Kettering Cancer Center)

Here’s a plain-language explanation of the science behind those anticancer effects.

At the chemical level, the most studied ingredient is withaferin A, one of many “withanolides” in Withania somnifera. In test-tube and animal experiments withaferin A looks like a multitool against cancer: it can directly damage cancer cells, block signals that help tumors survive and spread, and make standard drugs or radiation work better. Reviews that summarize hundreds of lab studies describe withaferin A as “pleiotropic” — meaning it hits many different molecular targets rather than only one. (PMC)

One major way it acts is by pushing cancer cells into programmed cell death (apoptosis). Withaferin A raises reactive oxygen species (ROS) inside tumor cells and triggers enzymes called caspases that execute cell death. In other experiments it interferes with proteins that normally keep damaged cells alive, so cancer cells are more likely to self-destruct. Those pathways have been observed across many cancer cell types in the lab. (Frontiers)

Another common effect is blocking growth and invasion signals. Withaferin A and some whole-plant extracts suppress pro-growth routes that cancers use (for example NF-κB and STAT3 signaling, and PI3K/Akt pathways). By interfering with these signals the compounds slow cell division, reduce inflammation that feeds tumors, and lower production of factors (like VEGF) that tumors use to build new blood vessels. That helps starve a tumor and limits its ability to grow and spread in animal models. (MDPI)

Withaferin A also affects the cytoskeleton and proteins that enable metastasis. It binds to structural proteins such as vimentin and disrupts the cell’s scaffolding, which can reduce cancer cell motility and invasion in laboratory assays. Several studies report reduced metastasis in mice treated with withaferin A. (PMC)

Finally, there are immune and treatment-sensitizing effects: some studies show ashwagandha extracts can stimulate parts of the immune system (natural killer cells, macrophages) and make tumor cells more sensitive to chemotherapy or radiation — either by weakening tumor defenses or by reversing mechanisms of drug resistance. That’s why researchers are exploring combination approaches in preclinical models and a few early clinical protocols. (dovepress.com)

Why MSK says “no”: the lab and animal results are promising, but they do not automatically mean the herb will treat human cancer safely or effectively. Most anticancer effects require concentrations that are easy to reach in a petri dish but hard to produce in a human without side effects. Human clinical trials that test whether ashwagandha (or isolated withaferin A) actually improves cancer outcomes are very limited; what exists so far mostly looks at symptom relief (fatigue, cognitive problems) or small pilot combinations, not proof of tumor-shrinking efficacy. Until well-designed large clinical trials exist, major cancer centers rightly advise caution. (Memorial Sloan Kettering Cancer Center)

Practical takeaway: the science supports strong preclinical anticancer activity and multiple believable mechanisms (pro-apoptosis, anti-growth signaling, anti-angiogenesis, anti-metastasis, immune modulation, and chemo/radio sensitization) — but clinical proof is lacking and supplements vary widely in strength and purity. If you or someone with cancer is considering ashwagandha, discuss it with the oncology team first because it can interact with treatments and has dose / safety questions that remain unresolved. (PMC)

Ashwagandha Leaf Extract: What a 2007 Study Discovered :

The 2007 study by Widodo and colleagues tested whether a leaf extract of ashwagandha (they called the active preparation “i-Extract”) could inhibit cancer. Using lab-grown human cells and tumour-formation tests in nude mice, the team found that the leaf extract impaired the growth of a range of cancer cells while having much less effect on normal cells. Through chemical fractionation they isolated a single active component—withanone—which showed the strongest tumour-inhibiting activity. Mechanistic experiments using gene-silencing showed that the extract’s killing effect depended on the tumour-suppressor protein p53: in cancer cells the extract activated p53, which in turn caused either cell-cycle arrest or programmed cell death (apoptosis). In short, the paper reported selective anti-tumour activity in cells and reduced tumour formation in mice, and it identified withanone as a promising active molecule that appears to work at least in part by activating p53. (PubMed)

It’s important to stress what the authors themselves said: these are preclinical findings (cell and animal work). They point to a biologically plausible anticancer action and a candidate compound, but they do not demonstrate safety or effectiveness in humans—clinical trials would be required to assess that. Later laboratory work from the same group and others explored additional mechanisms (for example, induction of reactive-oxygen-species signalling) that may contribute to the selective killing seen with the extract. (PMC)

(Source : ChatGPT)

Old Illustration Style :

To force an AI to generate an image in an old illustration style, think of the prompt like a recipe. Start by naming the exact style you want, then list the medium or techniques, specify the era or region, define colors and textures, add composition keywords, and finally include negatives to remove modern traits. A template could be: “[Subject]. In the style of a [specific era/style] such as Victorian wood-engraving, 19th-century etching, vintage children’s book illustration, or Art Nouveau poster. Medium: pen-and-ink, woodcut, etching, lithograph, or watercolor wash. Details: cross-hatching, stippling, limited palette, sepia toning, yellowed paper, visible paper grain, or halftone dots. Composition: frontal portrait, ornate border, decorative frame, or engraved plate layout. Mood: antique, fragile, slightly faded. —No modern elements, no photorealism, no digital artifacts.”

For example, you could write: “An owl perched on a branch, Victorian wood-engraving style, pen-and-ink cross-hatching, stippling, sepia toning, aged paper texture, ornate border —no photorealism, no vibrant neon colors.”

To get better results, reference specific artists or books, like “19th-century John Tenniel illustrations,” and add cues like “paper texture,” “ink bleed,” or “printer halftone” to enhance the aged look. If the image still looks too modern, strengthen the negatives by adding instructions such as “—no modern lighting” or “—no soft CGI look.” Iterate by tweaking one attribute at a time, for example increasing cross-hatching, darkening sepia tones, or making the paper grain more visible.

Simplistic Images :

To make an AI generate an image in a simplistic, low-detail style, you need to guide it with the right descriptive cues. Use keywords like “simplistic,” “minimal,” “low-detail,” “flat,” “clean,” “graphic,” “blocky shapes,” “bold outlines,” “large color fields,” and “uncluttered.” Referencing particular styles can also help, such as children’s book illustration, mid-century modern, pictogram, lino-cut, icon design, or naive art. For color and surface, ask for a limited palette, flat shading, no texture, no gradients, and high contrast. In terms of composition and linework, describe simple silhouettes, thick or consistent line weight, a centered subject, and plenty of negative space.

It’s also important to tell the AI what you don’t want. Use negatives like “no photorealism,” “no fine details,” “no intricate patterns,” “no texture,” or “no tiny highlights.” For example, a prompt could be: “Cute fox, minimal children’s-book style, low-detail, flat shading, limited 3-color palette, bold outlines, lots of negative space —no photorealism, no texture, no tiny details.” If the output still looks too busy, you can reinforce the simplification by repeating terms like “minimal” or “low-detail,” or adding instructions such as “reduce detail” or “simplify shapes.”

This method lets you control the AI to produce images that feel intentionally simple, clean, and uncluttered.

Rough Images :

To make an AI generate an image that looks “rough,” you want to focus on conveying texture, imperfection, and a hand-crafted feel. Describe the style using words like rough, sketchy, gritty, raw, hand-drawn, or unfinished. Mention the medium or technique that naturally produces rough textures, such as charcoal, pencil, ink wash, dry brush, scratchboard, or rough etching. You can also describe the surfaces, like grainy paper, canvas texture, brush strokes, or visible pencil marks. Encourage irregularity in the lines or shapes by using terms like jagged, uneven, wobbly, or smudged. For colors, a muted or uneven palette often helps, with visible streaks or gradients to avoid a clean, polished look. Include negatives like “no smooth gradients,” “no polished finish,” or “no perfect symmetry” to prevent the AI from producing something too clean or digital.

For example, a prompt might be: “A stormy landscape, rough hand-drawn charcoal style, sketchy lines, uneven shading, textured paper, smudges and jagged edges, muted colors —no smooth gradients, no digital polish, no perfect symmetry.” Iterating and adjusting these descriptors will help the AI capture that intentionally rough, imperfect, and expressive quality in your image.

Creating Decrepit Textures with AI :

To create an AI-generated texture that looks old or decrepit, the key is to emphasize signs of age, wear, and decay in your description. Use words like weathered, cracked, peeling, rusted, chipped, stained, faded, worn, distressed, or corroded. Specify the type of surface or material—wood, metal, stone, plaster, paper, or fabric—and describe how time has affected it, such as splintered wood, flaking paint, pitted metal, cracked plaster, torn paper, or frayed cloth. Color choices play an important role: muted, desaturated, sepia, or oxidized tones help create the impression of age. You can also include elements like dirt, dust, mold, rust streaks, moss, scratches, and scuffs to enhance the feeling of decay. Include negatives to avoid modern, clean, or polished looks, for example “no bright colors,” “no smooth surfaces,” or “no shiny materials.”

For instance, a prompt could be: “Old wooden floor texture, cracked and peeling paint, faded and stained, rough worn surface, dust and dirt in crevices —no bright colors, no polished finish, no new wood.” By iterating with variations in surface type, color, and degree of decay, the AI can generate textures that convincingly look aged, worn, or decrepit, perfect for backgrounds, objects, or environments in digital art.

(Source : ChatGPT)

Ashwagandha — the common name for the plant Withania somnifera — has one of the longest continuous histories of use of any medicinal plant. Its story begins in the Indian subcontinent, where the herb appears repeatedly in the classical Ayurvedic pharmacopeia as a tonic and “rasāyana” (rejuvenator). Ancient Ayurvedic texts such as the Charaka Saṃhitā and Sushruta Saṃhitā (themselves compilations and redactions of material that crystallized in the first centuries BCE–CE and later) recommend the root for strength, vitality, and for conditions now described as debility, nervous exhaustion and sexual dysfunction; traditional Sanskrit names — most famously “ashwagandha” (literally “horse-smell,” referring to the root’s aroma and the plant’s traditional attribution of conferring the strength of a horse) — reflect those uses. Modern reviews of Ayurvedic sources and ethnomedicine summarize these longstanding uses and quote the classical texts as their origin. (PMC)

Outside the Indian tradition the plant (or very similar “nightshade” herbs) was known in other old medical systems. Scholars have identified plants of the Withania/Solanaceae group in Greco-Roman herbal listings and in later Unani and folk traditions across North Africa and the Mediterranean; in short, the use of Withania-type plants for weakness, inflammation and postpartum care is attested beyond India long before modern botany formalized the species. (ahpa.org)

The transition from traditional medicine to botanical science began in the 18th century. In 1753 Carl Linnaeus described the plant under a different genus name (he recorded it as Physalis somnifera in his Species Plantarum), and later botanical work consolidated it under the genus Withania (the conserved name honors the early-19th-century English figure Henry Witham). By the 19th and early 20th centuries European and colonial botanists were recording its distribution across India, Nepal, Sri Lanka and parts of Africa and the Middle East, and herbarium specimens and pharmacopoeias began treating it as a discrete, identifiable species: Withania somnifera (L.) Dunal. (pza.sanbi.org)

Modern phytochemistry and pharmacology accelerated in the mid-20th century. Chemists isolated and characterized the plant’s distinctive steroidal lactones — the withanolides — that are now widely regarded as the main bioactive family in the species. The first withanolide to be isolated and described in the literature — withaferin A — was reported by Lavie and Yarden in 1962; since then hundreds of related withanolides and other constituents (alkaloids, sitoindosides, etc.) have been identified and studied for their biochemical activities. That chemical work changed ashwagandha from a vague “tonic” in Western eyes into a plant with definable molecules to test in laboratories. (RSC Publishing)

Laboratory and animal studies through the late 20th century produced a long list of possible mechanisms — anti-inflammatory, anti-oxidant, modulation of the hypothalamic–pituitary–adrenal (HPA) axis, neuroprotective and even anticancer actions — and those preclinical leads prompted the first controlled human studies in the 2000s and 2010s. Several early randomized, double-blind, placebo-controlled trials became touchstones for modern clinical interest. For example, a widely cited 2012 randomized, double-blind, placebo-controlled trial by Chandrasekhar and colleagues tested a high-concentration, full-spectrum root extract and reported significant reductions in perceived stress and serum cortisol versus placebo. Subsequent randomized trials explored related indications: a 2013 pilot study by Ambiye and colleagues examined spermatogenic effects in oligospermic men and reported large improvements in sperm count and motility after 90 days; a 2015 randomized trial by Wankhede et al. reported increases in muscle strength and mass and a rise in serum testosterone in healthy men undertaking resistance training; and several 2017–2019 trials (for example by Choudhary et al. and Lopresti et al.) examined cognitive function, insomnia, and anxiety with generally favorable results in small-to-moderate sized populations. These clinical studies gave the first controlled human evidence that some classical claims (stress-reduction, improvements in certain reproductive and performance parameters, sleep and cognition) could be measured in trials — while also revealing the need for larger, higher-quality studies. (PMC)

As trials accumulated, systematic reviews and meta-analyses began to appear. Over the last decade reviewers have pooled randomized trials for stress/anxiety and for sleep and reported statistically significant effects in pooled analyses, tempered by caveats about study quality, small sample sizes, heterogeneity of extracts and doses, and short follow-up periods. Government and public-health bodies have taken notice: the U.S. National Institutes of Health’s Office of Dietary Supplements now maintains an updated “Health Professional Fact Sheet” summarizing the evidence, typical doses used in trials (commonly 300–600 mg/day of standardized root extract), and known safety considerations (possible gastrointestinal side effects, sedation in some people, interactions and rare reports of liver injury), while emphasizing that the overall evidence base is still developing. (ScienceDirect)

In the last five to ten years the pace of research and commercialization has only accelerated. Dozens of randomized controlled trials, several larger meta-analyses, and a wave of nutraceutical products standardized for total withanolides have appeared; investigators are exploring formulations for mood and sleep, for sports performance and recovery, for male fertility, and as adjuvants in metabolic and neurodegenerative research. At the same time pharmacologists continue to study withanolides (including withaferin A) in cell and animal models for anti-inflammatory, immunomodulatory and anticancer effects — work that has generated potential drug leads but not yet clinical approvals for those indications. Regulatory and safety authorities now advise caution about product quality (variability between commercial extracts), dose, and contraindications (for example pregnancy, certain autoimmune or hormone-sensitive conditions). (MDPI)

Summing up: ashwagandha’s arc runs from an ancient Ayurvedic “rejuvenator” noted in millennia-old Indian medical texts through botanical classification in the 18th–19th centuries, to chemical discovery in the 1960s (withaferin A) and a modern clinical literature that began to solidify in the 2000s and 2010s with randomized human trials and meta-analyses. The plant’s traditional profile — an adaptogen used for weakness, stress and reproductive health — largely guided modern research questions, and clinical science has begun to corroborate some of those traditional uses while also introducing new, evidence-based caveats about dosing, standardization and safety. For readers interested in primary sources, good starting points are reviews of classical Ayurvedic references and ethnobotany, the 1962 chemical description of withaferin A, the 2012 Chandrasekhar randomized trial on stress, and the recent NIH Office of Dietary Supplements fact sheet summarizing contemporary clinical evidence and safety considerations. (PMC)

(Source : ChatGPT)

In the Ayurvedic tradition Ashwagandha (Withania somnifera) occupies a prominent place as a tonic and rejuvenative herb. Its Sanskrit name—ashva (horse) + gandha (smell)—literally refers to the strong, earthy odor of the fresh root and also evokes the plant’s classical reputation for imparting the vigor and stamina of a horse. For centuries Ayurvedic authors and practitioners have classified it among the rasayanas: remedies used to bolster vitality, preserve youthfulness, strengthen the body’s resilience, and support long life and well-being.

Classically it was used as a general restorative for people weakened by chronic illness, ageing, or hard labor. Ayurvedic texts and clinical practice describe it as a strengthening (balya), nourishing (brhmana) and aphrodisiac (vr̥ṣya) agent that supports reproductive health, muscle tone and overall stamina. It was also valued for calming and stabilizing the nervous system: prescribed in conditions of fatigue, mental restlessness and poor sleep, and frequently included in post-partum and convalescent regimens to restore “ojas” (the subtle essence of strength and immunity in Ayurvedic thought).

In traditional formulations the root is the primary part used: taken as a powdered herb with warm milk and ghee, prepared into medicated jams (avaleha) or oils, or used as a decoction. Externally, pastes and oils containing ashwagandha have been applied to sore joints and inflamed tissues. Because it is considered a rejuvenative, practitioners usually recommend it as part of a sustained therapeutic course rather than a one-off remedy, often combined with other herbs and dietary measures tailored to a person’s constitution (dosha) and condition.

While modern herbalists sometimes label ashwagandha an “adaptogen”—a convenient shorthand for its use in stress and fatigue—Ayurveda frames its effects in a broader, individualized system of balance, nourishment and longevity. As with most classical remedies, traditional use emphasizes practitioner guidance: dose, duration and the right formulation were chosen according to the person’s age, constitution and current state of health.

Here’s a short passage rendered as a clear, modern translation/paraphrase of the way classical Ayurvedic sources describe ashwagandha:

“Ashwagandha is counted among the foremost rasayanas and tonics. Its root strengthens the body, restores diminished vitality, and preserves youth; taken with milk and ghee it nourishes the tissues, stabilizes the mind, and promotes restful sleep. It is especially indicated for those weakened by prolonged illness, for the elderly, and for persons who need to rebuild strength and reproductive vigor. Its effect is steady and cumulative rather than immediate, so practitioners prescribe it as part of a sustained course tailored to the patient’s constitution (dosha) and condition.”

That passage is a paraphrase of classical descriptions (using traditional terms such as rasayana, ojas, balya and vr̥ṣya).

Here are a few short, interesting quotes (each with a source) that capture how Ayurveda views ashwagandha:

“Ashwagandha… is believed that after consuming the root, one gains powers similar to that of a horse.” (PMC)

“Since ancient times, it has been traditionally used in Ayurvedic medicine as a substance that strengthens the nervous system.” (PMC)

“Long life, good memory, intelligence, perfect health, youthfulness… are all obtained from Rasayana therapy.” — from the Rasayana chapter of the Ashtanga Hridaya (the classical context in which herbs such as ashwagandha are prescribed as rejuvenatives). (Easy Ayurveda Hospital)

“Withania somnifera … is a traditional Ayurvedic adaptogen used to enhance muscle strength, endurance, and overall health.” (Liebert Publishing)

“Ashwagandha… is noted for its Rasayana effects, potential aphrodisiac qualities, and ability to balance Vata.” (Bibliothèque de Sagesse)

(Source : ChatGPT)

Ashwagandha (Withania somnifera) can reduce inflammation because it contains natural compounds called withanolides, the most studied of which is withaferin A. These molecules interact with several of the same biochemical “switches” the body uses to start and sustain inflammation, and by calming those switches Ashwagandha helps lower the overall inflammatory response.

Inflammation itself is the body’s normal reaction to injury or infection: immune cells release signaling molecules called cytokines (for example TNF-α, IL-6 and IL-1β) and activate signaling pathways that produce redness, swelling and pain. Those reactions are useful for short periods, but when they remain active for a long time they can harm tissues and contribute to chronic disease. Ashwagandha’s compounds work at multiple points in this process to reduce both the signals and the biochemical traffic that keep inflammation going.

One important target is a protein complex known as NF-κB, which acts like a master switch for many inflammatory genes. Withanolides, including withaferin A, have been shown in laboratory studies to interfere with NF-κB activation; when that master switch is less active, cells produce fewer inflammatory chemicals. Ashwagandha also affects other signaling routes that amplify inflammation, such as MAPK pathways, so the overall amplification of the inflammatory response is reduced.

Beyond switching off signaling pathways, Ashwagandha tends to lower levels of key inflammatory molecules. In experimental studies it has been associated with decreases in cytokines like TNF-α, IL-6 and IL-1β, which are commonly elevated in chronic inflammation. The plant’s extracts have also been shown to reduce the activity of enzymes that make inflammatory mediators—specifically COX-2, which helps produce prostaglandins that cause pain and swelling, and iNOS, which produces nitric oxide that can worsen inflammation. By cutting activity at these enzymes, fewer inflammatory chemicals are produced at the tissue level.

Inflammation and oxidative stress feed each other, and Ashwagandha appears to help on that front as well. Some components activate the Nrf2 pathway, a cellular defense system that increases antioxidant enzymes. Strengthening antioxidant defenses reduces oxidative damage and indirectly weakens inflammatory signaling, creating another route by which Ashwagandha can lower inflammation.

Most of what we know about these mechanisms comes from cell and animal studies; those experiments consistently show effects on NF-κB, MAPK, cytokines and inflammatory enzymes. Human trials are fewer and use different extract types and doses, but several clinical studies and reviews report reductions in blood markers of inflammation (for example C-reactive protein) and improvements in symptoms related to chronic inflammation. Because study methods and supplement quality vary, the human evidence is promising but not uniform.

It’s important to be cautious: “natural” does not guarantee safety or consistent effect for everyone. Ashwagandha can interact with medications and cause side effects in some people, and different supplements contain different amounts of active withanolides, so results will vary between products. Anyone considering Ashwagandha for inflammatory issues should discuss it with a healthcare professional and use a reputable product.

In short, Ashwagandha contains withanolides that can dial down central inflammatory switches (like NF-κB and MAPK), reduce inflammatory cytokines and enzymes, and boost antioxidant defenses; together these actions help explain why the plant can have anti-inflammatory effects, according to laboratory, animal and some human studies.

(Source : ChatGPT)

There is reasonable clinical evidence that ashwagandha (Withania somnifera) can provide real health benefits for some people, but the effects are usually modest, depend on the extract and dose, and are not miraculous or guaranteed for everyone.

The strongest and most consistent finding from human trials is that ashwagandha can reduce perceived stress and symptoms of anxiety and lower levels of the stress hormone cortisol. Several randomized, double-blind, placebo-controlled trials found that people taking standardized root extracts reported less stress and anxiety and showed reductions in morning cortisol, and researchers think part of the effect comes from modulation of the hypothalamic–pituitary–adrenal (HPA) axis. (PubMed)

Closely related to the stress results, a number of studies also report improvements in sleep quality and sleep onset in people who take ashwagandha for several weeks. Most clinical trials used standardized root extracts in the roughly 250–600 mg/day range and tested them for 6–12 weeks; pooled analyses and health-agency summaries describe modest but measurable benefits for sleep in adults with either insomnia or sleep complaints. (Bureau des Suppléments Alimentaires)

Beyond stress and sleep, growing—but still not definitive—evidence suggests ashwagandha may help with certain aspects of physical performance, body composition, and reproductive health in men. Small randomized trials and recent narrative reviews have reported modest increases in muscle strength and recovery when ashwagandha is combined with resistance training, small improvements in body-fat percentage, and in some trials improvements in sperm parameters and testosterone in men with low baseline values. These findings look promising but vary with the specific extract used, the population studied, and study quality, so they’re encouraging rather than conclusive. (PMC)

Why might it work? The herb contains steroidal lactones called withanolides plus other compounds that have anti-inflammatory, antioxidant and neuromodulatory actions in laboratory studies. Those activities map onto the clinical signals we see: lowering oxidative stress and inflammation can protect cells and brain function, while modulation of stress pathways (HPA axis) and neurotransmitter systems can reduce anxiety and improve sleep. In short, a combination of hormonal (cortisol) modulation and direct cellular protective effects likely explains the observed benefits in humans. (PubMed)

Safety and caveats: ashwagandha is generally well tolerated in short-term trials, but it’s not risk-free. Reported side effects include mild gastrointestinal upset, drowsiness, and occasional headaches. Important safety warnings include avoiding ashwagandha during pregnancy (some data and regulatory reviews advise against it because of potential adverse effects on pregnancy) and caution for people taking medications for thyroid disease, blood pressure, diabetes, or sedatives because interactions are possible. Long-term safety data are still limited and product quality varies widely between brands, so choosing standardized, third-party tested products and discussing use with a clinician is sensible. (RIVM)

Bottom line: if your goal is to reduce stress or improve sleep, there is good evidence that a standardized ashwagandha root extract taken at commonly studied doses (roughly 250–600 mg/day) can help for many people; other effects (muscle, fertility, metabolic markers) show promise but need more and larger trials to be definitive. Always check with your healthcare provider before starting any supplement, especially if you’re pregnant, breastfeeding, have chronic medical conditions, or take prescription medications.

(Source : ChatGPT)